Probiotic Add-on Therapy in the First-episode Schizophrenia: A Randomized Controlled Trial
عنوان مقاله: Probiotic Add-on Therapy in the First-episode Schizophrenia: A Randomized Controlled Trial
شناسه ملی مقاله: JR_CJNS-9-4_004
منتشر شده در در سال 1402
شناسه ملی مقاله: JR_CJNS-9-4_004
منتشر شده در در سال 1402
مشخصات نویسندگان مقاله:
Robabeh Soleimani - Department of Psychiatry, Kavosh Cognitive Behavior Sciences and Addiction Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
Mir Mohammad Jalali - Department of Otolaryngology Head and Neck Surgery, Otorhinolaryngology Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
Hoda Bakhtiari - Department of Psychiatry, Kavosh Cognitive Behavior Sciences and Addiction Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
Fatemeh Eslamdoust-Siahestalkhi - Department of Psychiatry, Kavosh Cognitive Behavior Sciences and Addiction Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
Seyede Melika Jalali - Department of Pharmacology, Faculty of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
خلاصه مقاله:
Robabeh Soleimani - Department of Psychiatry, Kavosh Cognitive Behavior Sciences and Addiction Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
Mir Mohammad Jalali - Department of Otolaryngology Head and Neck Surgery, Otorhinolaryngology Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
Hoda Bakhtiari - Department of Psychiatry, Kavosh Cognitive Behavior Sciences and Addiction Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
Fatemeh Eslamdoust-Siahestalkhi - Department of Psychiatry, Kavosh Cognitive Behavior Sciences and Addiction Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
Seyede Melika Jalali - Department of Pharmacology, Faculty of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
Background: Some evidence supports probiotics’ beneficial effects on clinical symptoms of patients
with schizophrenia and relieving unwanted frequently associated side effects of antipsychotic drugs
such as constipation, obesity, and metabolic disorders.
Objectives: This study aimed to assess the effect of probiotic supplements on clinical psychiatry
symptoms and metabolic indices in patients with schizophrenia.
Materials & Methods: First-episode schizophrenic patients were randomly assigned to probiotics
and placebo groups in a randomized controlled trial that took ۱۲ weeks. The primary outcomes were
the brief psychiatric rating scale (BPRS) change scores and positive and negative syndrome scale
(PANSS). The secondary outcomes were clinical global impression-improvement scale (CGI-S),
blood pressure (BP), body mass index (BMI), lipid profiles, and fasting blood sugar (FBS).
Results: A total of ۶۲ patients were considered for the intention-to-treat analysis (mean age, ۳۴.۷
years; ۲۳ women; ۳۹ men). The results showed no significant differences in the primary objectives
between the probiotic and placebo groups. In the probiotic group, subjects had lower levels of all
biochemical variables (triglycerides, cholesterol, and FBS) compared to the subjects in the placebo
group (standardized mean difference -۴.۳, -۲.۸, and -۴.۶, respectively; P<۰.۰۵).
Conclusion: We found that by adding probiotics to oral antipsychotics, BPRS or PANSS scores do not
improve. However, Cohen’s d for biochemical variables showed a medium to large effect size. This
study suggests probiotic supplementation may regulate and control triglycerides, cholesterol, and FBS
levels. Future studies are recommended to demonstrate these findings in the confirmatory analysis.
کلمات کلیدی: Probiotics, Microbiota, Schizophrenia, Mental disorders, Antipsychotic agents
صفحه اختصاصی مقاله و دریافت فایل کامل: https://civilica.com/doc/1859506/